Harbour BioMed Out-licenses Bispecific to AstraZeneca in $350 Million Agreement
publication date: Apr 7, 2022
Harbour BioMed out-licensed global rights for a pre-clinical bispecific candidate to AstraZeneca in a $350 million agreement. HBM7022 targets a tumor-associated antigen (Claudin18.2) and CD3, a combination that HBM believes will activate T cells and eliminate tumors. AZ will test the candidate in gastric and pancreatic cancers. HBM will receive $25 million upfront and as much as $325 million in milestones, plus royalties. It said the agreement for HBN7022 is a significant validation of its drug discovery technology. HBM is headquartered in Cambridge, MA, with facilities in Suzhou and Rotterdam. More details....
Stock Symbols: (HK: 02142) (NSDQ: AZN)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.